JP2019532105A5 - - Google Patents

Info

Publication number

JP2019532105A5

JP2019532105A5 JP2019541893A JP2019541893A JP2019532105A5 JP 2019532105 A5 JP2019532105 A5 JP 2019532105A5 JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019532105 A5 JP2019532105 A5 JP 2019532105A5

Authority

JP

Japan

Prior art keywords

fluid

dry eye

severe dry

surgery

treating severe

Prior art date

2017-10-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012530 fluid Substances 0.000 claims 30
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims 15
• 206010013774 Dry eye Diseases 0.000 claims 15
• 239000003755 preservative agent Substances 0.000 claims 15
• 238000001356 surgical procedure Methods 0.000 claims 12
• 230000002335 preservative effect Effects 0.000 claims 8
• 239000012867 bioactive agent Substances 0.000 claims 6
• 239000003599 detergent Substances 0.000 claims 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
• 239000004480 active ingredient Substances 0.000 claims 3
• 210000000170 cell membrane Anatomy 0.000 claims 3
• 230000002209 hydrophobic effect Effects 0.000 claims 3
• 208000014674 injury Diseases 0.000 claims 3
• 230000008733 trauma Effects 0.000 claims 3
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
• VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims 2
• 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
• 229920002413 Polyhexanide Polymers 0.000 claims 2
• 230000001580 bacterial effect Effects 0.000 claims 2
• 229960000686 benzalkonium chloride Drugs 0.000 claims 2
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
• 229940124447 delivery agent Drugs 0.000 claims 2
• 239000006196 drop Substances 0.000 claims 2
• 239000003792 electrolyte Substances 0.000 claims 2
• 230000007705 epithelial mesenchymal transition Effects 0.000 claims 2
• 229920002674 hyaluronan Polymers 0.000 claims 2
• 229960003160 hyaluronic acid Drugs 0.000 claims 2
• 239000011780 sodium chloride Substances 0.000 claims 2
• 230000000638 stimulation Effects 0.000 claims 2
• 239000000126 substance Substances 0.000 claims 2
• 208000023275 Autoimmune disease Diseases 0.000 claims 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
• ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
• 208000010412 Glaucoma Diseases 0.000 claims 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
• 241001465754 Metazoa Species 0.000 claims 1
• 229910019142 PO4 Inorganic materials 0.000 claims 1
• 208000025747 Rheumatic disease Diseases 0.000 claims 1
• 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
• 239000013543 active substance Substances 0.000 claims 1
• 239000013566 allergen Substances 0.000 claims 1
• 239000003242 anti bacterial agent Substances 0.000 claims 1
• 229940088710 antibiotic agent Drugs 0.000 claims 1
• 239000000872 buffer Substances 0.000 claims 1
• 230000003139 buffering effect Effects 0.000 claims 1
• 229960004926 chlorobutanol Drugs 0.000 claims 1
• 238000004132 cross linking Methods 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 229940009662 edetate Drugs 0.000 claims 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
• 231100000040 eye damage Toxicity 0.000 claims 1
• 239000003889 eye drop Substances 0.000 claims 1
• -1 haptens Substances 0.000 claims 1
• 230000003054 hormonal effect Effects 0.000 claims 1
• 239000002955 immunomodulating agent Substances 0.000 claims 1
• 229940121354 immunomodulator Drugs 0.000 claims 1
• 229960003444 immunosuppressant agent Drugs 0.000 claims 1
• 239000003018 immunosuppressive agent Substances 0.000 claims 1
• 239000007943 implant Substances 0.000 claims 1
• 239000012535 impurity Substances 0.000 claims 1
• 208000015181 infectious disease Diseases 0.000 claims 1
• 150000002500 ions Chemical class 0.000 claims 1
• 230000007794 irritation Effects 0.000 claims 1
• 125000003473 lipid group Chemical group 0.000 claims 1
• 230000000813 microbial effect Effects 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 230000003204 osmotic effect Effects 0.000 claims 1
• 239000007800 oxidant agent Substances 0.000 claims 1
• 230000001590 oxidative effect Effects 0.000 claims 1
• 125000005430 oxychloro group Chemical group 0.000 claims 1
• 239000002245 particle Substances 0.000 claims 1
• 230000035699 permeability Effects 0.000 claims 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
• 239000010452 phosphate Substances 0.000 claims 1
• 239000008363 phosphate buffer Substances 0.000 claims 1
• 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
• 230000005855 radiation Effects 0.000 claims 1
• 238000002271 resection Methods 0.000 claims 1
• 230000002207 retinal effect Effects 0.000 claims 1
• 150000003839 salts Chemical class 0.000 claims 1
• 229910052708 sodium Inorganic materials 0.000 claims 1
• 239000011734 sodium Substances 0.000 claims 1
• 229940010747 sodium hyaluronate Drugs 0.000 claims 1
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
• 239000000243 solution Substances 0.000 claims 1
• 229940075582 sorbic acid Drugs 0.000 claims 1
• 235000010199 sorbic acid Nutrition 0.000 claims 1
• 239000004334 sorbic acid Substances 0.000 claims 1
• 230000002269 spontaneous effect Effects 0.000 claims 1
• 230000000087 stabilizing effect Effects 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 238000011200 topical administration Methods 0.000 claims 1
• 231100000167 toxic agent Toxicity 0.000 claims 1
• 239000003440 toxic substance Substances 0.000 claims 1